Immunodynamics of explanted human tumors for immuno‐oncology

Immunodynamics of explanted human tumors for immuno‐oncology

Abstract Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex func...

Full description

Saved in:
Bibliographic Details
Main Authors: Agathe Dubuisson, Jean‐Eudes Fahrner, Anne‐Gaëlle Goubet, Safae Terrisse, Nicolas Voisin, Charles Bayard, Sebastien Lofek, Damien Drubay, Delphine Bredel, Séverine Mouraud, Sandrine Susini, Alexandria Cogdill, Lucas Rebuffet, Elise Ballot, Nicolas Jacquelot, Vincent Thomas de Montpreville, Odile Casiraghi, Camélia Radulescu, Sophie Ferlicot, David J Figueroa, Sapna Yadavilli, Jeremy D Waight, Marc Ballas, Axel Hoos, Thomas Condamine, Bastien Parier, Christophe Gaudillat, Bertrand Routy, François Ghiringhelli, Lisa Derosa, Ingrid Breuskin, Mathieu Rouanne, Fabrice André, Cédric Lebacle, Hervé Baumert, Marie Wislez, Elie Fadel, Isabelle Cremer, Laurence Albiges, Birgit Geoerger, Jean‐Yves Scoazec, Yohann Loriot, Guido Kroemer, Aurélien Marabelle, Mélodie Bonvalet, Laurence Zitvogel
Format: Article
Language:English
Published: Springer Nature 2020-12-01
Series:EMBO Molecular Medicine
Subjects:
“in sitro” assay
cancer
immune checkpoint inhibitors
immunomonitoring
precision oncology
Online Access:https://doi.org/10.15252/emmm.202012850
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno‐assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti‐PD‐1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.
ISSN:1757-4676
1757-4684

Similar Items